Several new medications are reshaping diabetes management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted promising options. Retatrutide, a double GIP and GLP-1 receptor agonist, demonstrates significant body mass decrease along with enhanced glycemic regulation. Cagrillintide, another GLP-1 agonist, is presently in